血脂康在家族性高胆固醇血症杂合子中的应用研究

Application of Xuezhikang in heterozygous with familial hypercholesterolemia

目的:探讨使用血脂康治疗家族性高胆固醇血症(familial hypercholesterolemia,FH)杂合子的安全性及疗效。方法:回顾性分析2016年4月至2019年12月,就诊安贞医院门诊的100例FH杂合子,平均年龄(35.1+5.9)岁,根据治疗方案分为阿托伐他汀20mg组50例,每晚1次治疗,血脂康组50例给予血脂康2粒(0.6g),每日2次口服。4周后观察两组患者血脂、肝肾功能、CK和血糖变化。结果:两组治疗4周后TC和LDL-C水平较治疗前显著下降,差异有统计学意义(P<0.05)。阿托伐他汀组TC、LDL-C和TG水平较治疗前分别下降44.0%、37.7%和15.1%;血脂康组TC、LDL-C和TG水平较治疗前分别下降41.5%、37.9%和21.4%,两组治疗后TG水平差异有统计学意义(P<0.05)。治疗前后两组患者肝肾功能和CK未见明显改变。结论:血脂康显著降低FH杂合子的TC及LDL-C水平,可作为FH杂合子降脂治疗的一种选择药物。

Objective:To explore the safety and efficacy of Xuezhikang(XZK)in treating heterozygous with familial hypercholesterolemia(heFH).Methods:A total of 100 heFH treated in Anzhen Hospital from 2016-4 to 2019-12 were retrospectively studied.Patients were divided into two groups,50 cases each group.One group was treated with atorvastatin 20mg,and the other group was treated with XZK 0.6g twice a day.After 4 weeks,the changes of lipid level,liver and kidney function,creatine kinase and blood glucose were observed in two groups.Results:The TC and LDL-C of the two groups,TG in the observation group decreased significantly after 4 weeks treatment(P<0.05).The level of TC,TG and LDL-C in the atorvastatin group decreased by 44.0%,37.7%,15.1%respectively after 4 weeks compared with that before treatment.TC and LDL-C level in the XZK group decreased by 41.5%,37.9%,21.4%respectively.There was significant difference in the range of TG reduction between two groups(P<0.05);there was no significant change in liver and kidney function and creatine kinase in the observation group before and after treatment.Conclusions:XZK therapy could decrease levels of TC and LDL-C in heFH with good tolerance;it has been a safe and effective method for treating heFH.